Bone-Building drug under the microscope: could speed up new osteoporosis treatments

NCT ID NCT01293292

Completed Knowledge-focused Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how teriparatide (Forsteo), a daily injection, builds new bone in postmenopausal women with osteoporosis. Nineteen women took the drug for two years. The goal was not to test if it works, but to understand exactly how it changes bone density and turnover over time. This knowledge could help researchers develop and test new bone-building drugs faster.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Teriparatide (Forsteo)
What this could lead to: If successful, this study could help researchers develop new bone-building drugs for osteoporosis more quickly.
What could go wrong: This is a small, early-stage study with only 19 participants, so results may not apply to everyone. It focuses on understanding how the drug works, not on proving it is a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPOROSIS

Contacts and locations

Locations

Sheffield Teaching Hospitals NHS Foundation Trust

Sheffield, South Yorkshire, S5 7AU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.